Cell:EGFR在自噬发生过程中的激酶非依赖性作用

2015-01-20 佚名 生物谷

近日,国际生物学顶尖期刊cell 刊登了来自麦迪逊威斯康星大学Richard A. Anderson研究小组的一项最新研究成果,他们通过研究发现非激活型EGFR能够通过与癌蛋白LAPTM4B相互作用参与自噬起始过程,而这一过程并不依赖于EGFR的激酶活性。这条信号通路可能对于控制肿瘤代谢,在代谢应激情况下促进肿瘤细胞存活具有重要意义。   研究人员指出,自噬是细胞在营养缺乏情

近日,国际生物学顶尖期刊cell 刊登了来自麦迪逊威斯康星大学Richard A. Anderson研究小组的一项最新研究成果,他们通过研究发现非激活型EGFR能够通过与癌蛋白LAPTM4B相互作用参与自噬起始过程,而这一过程并不依赖于EGFR的激酶活性。这条信号通路可能对于控制肿瘤代谢,在代谢应激情况下促进肿瘤细胞存活具有重要意义。
 
研究人员指出,自噬是细胞在营养缺乏情况下维持存活的一种可诱导性保护过程,但自噬在肿瘤研究中的作用具有两面性,一般认为自噬能够抑制肿瘤的发生,但在肿瘤细胞受到代谢应激的时候,自噬对肿瘤细胞具有保护性作用,能够促进肿瘤细胞的存活。研究发现,在多种肿瘤细胞中均发现EGFR表达上调,EGFR信号能够通过激活PI3K/AKT/mTOR信号通路或者通过磷酸化抑制beclin1进而抑制自噬过程,因此在肿瘤细胞中抑制EGFR信号通路能够诱导自噬过程的发生,但同时还发现在某些EGFR过表达的肿瘤细胞中,也会诱导自噬过程,并且对于维持肿瘤细胞的生长和存活具有重要作用,这提示研究者,EGFR或许在自噬发生过程中存在激酶非依赖性作用。
 
研究人员通过在MDA-MB-231细胞中敲低EGFR发现,基础状态下和血清饥饿刺激诱导的自噬过程均受到抑制,说明EGFR对于自噬发生具有重要作用。而后,研究人员发现,EGFR与 LAPTM4B在细胞内涵体中存在部分共定位,并且两者能够发生相互作用从而在内涵体中相互稳定,同时LAPTM4B对于自噬过程的发生至关重要。该文章发现,EGFR与LAPTM4B对自噬发生的影响还需要Sec5的作用,它们能够促进Rubicon与Beclin1的解离从而启动自噬过程。
 
综上所述,与之前研究结果不同,该文章发现EGFR能够诱导肿瘤细胞中自噬过程的发生,并且这一作用不依赖于EGFR的激酶活性。这一研究成果对于我们理解代谢刺激下肿瘤细胞生长存活机制具有重要意义。
 
原始出处

Xiaojun Tan1, Narendra Thapa1, Yue Sun1, Richard A. Anderson1.A Kinase-Independent Role for EGF Receptor in Autophagy Initiation.Cell.2014
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959248, encodeId=d2a1195924868, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon May 04 23:08:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868997, encodeId=6dae186899e9d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jun 20 10:08:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495931, encodeId=c1ad149593150, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Thu Jan 22 00:08:00 CST 2015, time=2015-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534265, encodeId=c492153426525, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Jan 22 00:08:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]
    2015-05-04 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959248, encodeId=d2a1195924868, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon May 04 23:08:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868997, encodeId=6dae186899e9d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jun 20 10:08:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495931, encodeId=c1ad149593150, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Thu Jan 22 00:08:00 CST 2015, time=2015-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534265, encodeId=c492153426525, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Jan 22 00:08:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959248, encodeId=d2a1195924868, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon May 04 23:08:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868997, encodeId=6dae186899e9d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jun 20 10:08:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495931, encodeId=c1ad149593150, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Thu Jan 22 00:08:00 CST 2015, time=2015-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534265, encodeId=c492153426525, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Jan 22 00:08:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]
    2015-01-22 redcrab
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959248, encodeId=d2a1195924868, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon May 04 23:08:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868997, encodeId=6dae186899e9d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jun 20 10:08:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495931, encodeId=c1ad149593150, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Thu Jan 22 00:08:00 CST 2015, time=2015-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534265, encodeId=c492153426525, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Jan 22 00:08:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]
    2015-01-22 liuyiping

相关资讯

Nature子刊:抗癌效果与自噬有关

在肿瘤受到抗癌药物的攻击时,一些较敏感的细胞死亡,另一些有抵抗力的细胞存活下来。科罗拉多大学癌症中心的一项研究显示,这些敏感细胞和抵抗细胞之间的差异在于,细胞通过自噬净化自己的能力不同。文章发表在Nature Cell Biology杂志上。 “举例来说,如果我们用IC-50的药物处理细胞,那么50%的细胞会死亡,而另外50%的细胞能够存活。为什么在有些细胞死亡的同时

自噬研究中的实验技术方法介绍

自噬的过程:  步骤1:细胞接受自噬诱导信号后,在胞浆的某处形成一个小的类似“脂质体”样的膜结构,然后不断扩张,但它并不呈球形,而是扁平的,就像一个由2层脂双层组成的碗,可在电镜下观察到,被称为Phagophore,是自噬发生的铁证之一。  步骤2:Phagophore不断延伸,将胞浆中的任何成分,包括细胞器,全部揽入“碗”中,然后“收口”,成为密闭的球状的autophag

综述:细胞自噬与凋亡的交互作用

细胞自噬又称Ⅱ型程序性细胞死亡,参与了多种疾病的发生和发展。自噬与凋亡之间存在着复杂的交互调控——二者能被多种应激刺激共同激活、共享多个调节分子,甚至互相协调转化等。全面深入研究自噬与凋亡之间的交互作用机制,将为肿瘤等疾病的认知及治疗带来突破性进展。细胞死亡是被周密调控的复杂过程。凋亡,作为第一个被认定的程序性细胞死亡程序(programmed cell death, PCD),其作用及

自噬--细胞的守护神(上)

tor/uploadfile/201402/20140225094530393.jpg" height="235" width="562"> More effects of autophagy     Image source Beyond its cell-autonomous action, autophagy can reduce age-rela

自噬系统和蛋白酶体系统之间的相互联系

 在真核细胞中已发现两条主要降解途径,即自噬系统和蛋白酶体系统.长期以来,这两条降解途径一直被认作是完全 独立的路径,然而最近的证据强烈提示,这两条主要降解途径之间相互联系.其中,发现干扰这两条途径的任一条可影响另一条途径的活性,抑制蛋白酶体可刺激自 噬活性.同时发现泛素的作用比先前想象更广泛,不仅具有标记蛋白酶体降解蛋白质这一 “经典作用”,还涉及自噬-溶酶体途径降解底物泛素化

Cell Rep:自噬令垂死的癌细胞复活

凋亡能够从内部撕碎癌细胞,但最近科学家们发现,这些在死亡线上挣扎的癌细胞能够通过增强自噬而复活,这项研究发表在Cell旗下Cell Reports杂志上。文章向人们展示了,癌细胞从凋亡中幸存的分子机制,而这一机制有助于进一步理解癌细胞对化疗药物所产生的抵抗。“这项研究带给我们的启示是,抑制自噬有助于减少上述情况的发生,帮助化疗药物彻底杀死癌细胞,”文章的资深作者,科罗拉多大学癌症中心的Andrew